In 1998, the results of the INCAS randomized double-blind clinical trial examining a combination of Nevirapine, Didanosine and Zidovudine as treatment for HIV-positive patients was published in the Journal of the American Medical Association.
Montaner was also central in the creation and implementation of the Treatment as Prevention strategy (TasP) [REF].